BCR-ABL Independent Resistance Mechanisms to Chronic Myeloid Leukemia

Ale Eba, Syed Tasleem Raza*, Sanchita Srivastava, Kaynat Fatima, Saliha Rizvi, Farzana Mahdi
Central Research Laboratory, Molecular Diagnostic Unit, Department of Biochemistry, ERA’S Lucknow Medical College, ERA University, Lucknow-226003, Uttar Pradesh, India

*Correspondence Email Address: [email protected]


In this review, we will focus on BCR-ABL-independent mechanisms which may have a clinical impact for CML patient therapeutic management. Of note, BCR-ABL independent mechanisms of resistance to TKI are expected to vary from those involving resistance or failure after allogeneic-transplantation, which are predominantly associated with immune system dysregulation. While excellent progress has been made through the introduction of targeted molecular therapy over the last two decades, new strategies to eliminate MRD and increase the pool of candidates eligible for trials of TFR are needed. Eliminating TKI resistance and LSC persistence by dual targeting of BCR-ABL1 and alternative pathways appears to be the most promising therapeutic avenue to decrease leukemic disease burden and potentiate “operational cures.”

Keywords: BCR-ABL, Independent Resistance, Chronic Myeloid Leukemia
Citation: Ale Eba, Syed Tasleem Raza, Sanchita srivastava, Kaynat Fatima, Saliha Rizvi, Farzana Mahdi. BCR-ABL Independent Resistance Mechanisms to Chronic Myeloid Leukemia: A Review. Canadian Journal of Clinical Nutrition. 2023; 11 (2): 102-117.

DOI: https://dx.doi.org/10.14206/canad.j.clin.nutr.2023.02.09